The global genomics market is growing steadily, and is expected to reach between $25 billion and $40 billion by 2025, according to market analysts.
Clinical decision support software developer InsightRX said today it will partner with Premier, a healthcare improvement company with 4,000 member U.S. hospitals and health systems, on a precision medicine collaboration designed to individualize medication dosing for drugs used in treating infectious disease. The collaboration, whose value was not disclosed, will integrate InsightRX's cloud-based precision dosing platform, InsightRX Nova, with Premier's...
This single-arm phase II study investigating two cycles of atezolizumab achieved the primary efficacy endpoint, showing a pathological complete response rate of 31%.
The FDA has granted marketing authorization to NantHealth’s Omics Core test, the company said today, clearing what it said is the nation’s first whole exome tumor-normal in vitro diagnostic (IVD) designed to measure overall tumor mutational burden (TMB) in cancer tissue. Omics Core is the first FDA authorized custom-targeted whole exome sequencing platform to report both overall TMB in tumor...
The pilot project will provide information for 147 genes that are well-established indicators of increased risk for certain diseases for which clinical treatment guidelines are established.
As the use of genomic testing increases, many doctors are failing to discuss the costs of these tests with their patients, leaving them at risk of unexpected medical bills.
NanoString Technologies has announced the launch of nCounter Human Organ Transplant, a gene expression panel for researchers to evaluate the human immune response following organ transplantation.
Through the acquisition, Invitae will gain access to Clear Genetics' chatbot named Gia, short for “Genetic Information Assistant,” which is designed to offer patients guidance for understanding test results.
Confera Dx is currently in development with the intention to be made available next year as a laboratory-developed test performed by Lexent in a CLIA-certified laboratory with the intention of developing a distributed in vitro diagnostic at a later date.
The Sentosa SQ HIV-1 Genotyping Assay uses the plasma of patients infected with human immunodeficiency virus-1 and is the first and only HIV-1 genotyping NGS assay currently available on the market to receive FDA marketing authorization.